Bird Rock Bio is a clinical stage biopharmaceutical company focused on developing innovative immuno-inflammatory regulators.  Backed by leading biotechnology venture investors, our strategy leverages biologic targets with substantial human proof of mechanism for the development of novel, best in class therapeutic antibodies with significant clinical and commercial differentiation.

RYI-018

First-in-Class, Only-in-Class peripheral antagonist antibody to Cannabinoid Receptor 1 (CB1)

GERILIMZUMAB

Novel antibody targeting IL-6 cytokine for the treatment of Rheumatoid Arthritis (RA)